Lipum AB (publ) has published the interim report Q2 for the period January-June 2025. Below is a summary, a complete report (only in Swedish) is available on the company's website. Financial summary January – June 2025Other operating income: 760 KSEK (94)Result after financial items: -36 618 KSEK (-28 109)Cash and cash equivalents as of June 30: [...]
Lipum AB (publ) has appointed Tobias Helgesson as its new Chief Financial Officer (CFO). He succeeds Marina Norberg, who will remain with the company during a transitional period to ensure continuity and a smooth handover. Tobias Helgesson holds a bachelor’s degree in business administration from Lund University. He brings over 20 years of professional experience, [...]
The previously announced publication date for the interim report Q2 2025 was August 14. The publication has now been postponed to August 28, 2025. ContactsOla Sandborgh, CEOola.sandborgh@lipum.se+46 72 218 80 21Web: www.lipum.se About UsLipum AB (publ) is a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. [...]
Lipum AB (publ) today announces the allocation of warrants in series TO A 2025/2028 and TO B 2025/2028, as resolved at the company’s Annual General Meeting held on June 16, 2025. During the period June 16 - 30, employees, key consultants, and board members were given the opportunity to subscribe for warrants in Lipum at [...]
The shareholders of Lipum are invited to the Annual General Meeting on June 16, 2025, at 1:00 PM at Lipum’s office, Tvistevägen 48C, 907 36 Umeå. The annual report is available on the company’s website (only in Swedish).In the annual report, CEO Ola Sandborgh comments: "With 2024 behind us, I can proudly state that it [...]
Lipum AB (publ) has published the interim report Q1 for the period January-March 2025. Below is a summary, a complete report (only in Swedish) is available on the company's website. Financial summary January – March 2025Other operating income: 492 KSEK (94)Result after financial items: -19 010 KSEK (-9 313)Cash and cash equivalents as of March 31: [...]
Lipum AB (publ) announces the completion and publication of the Clinical Study Report (CSR) for its First-in-Human (FIH) Phase I trial evaluating SOL-116. The study investigated single ascending doses (SAD) and multiple doses (MD) of SOL-116 in healthy volunteers, as well as a single dose in patients with mild rheumatoid arthritis (RA), and the findings [...]
The previous date for the Annual General Meeting for the financial year 2024 was May 14, 2025, but is now postponed to June 16, 2025. ContactsOla Sandborgh, CEOola.sandborgh@lipum.se+46 72 218 80 21Web: www.lipum.se About UsLipum AB (publ) is a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory [...]
Lipum AB (publ) has published the Q4 interim and year-end report for 2024. Below is a summary, a complete report (only in Swedish) is available on the company's website. Financial summary January – December 2024Other operating income: 911 KSEK (165)Result after financial items: -55 516 KSEK (-37 178)Cash and cash equivalents as of December 31: 6 [...]
Lipum AB (publ) announces the completion of its phase I clinical trial (LPM-116-001) evaluating SOL-116, with positive results. The study confirmed SOL-116’s favourable safety, tolerability, and predictable pharmacokinetics, supporting a once-monthly dosing regimen. Furthermore, exploratory analyses confirmed that SOL-116 effectively suppressed BSSL in both healthy volunteers and rheumatoid arthritis (RA) patients. These findings mark a [...]